Delamanid
242-07-208
Phase 2 small_molecule completed
Quick answer
Delamanid for Tuberculosis, Multidrug-Resistant is a Phase 2 program (small_molecule) at Otsuka Beijing Research Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Otsuka Beijing Research Institute
- Indication
- Tuberculosis, Multidrug-Resistant
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed